Opinion|Videos|April 21, 2025
Treatment Sequencing in Disease Progression in EGFRm NSCLC
Panelists discuss how, after the MARIPOSA regimen, second-line therapy selection depends on resistance mechanisms, prior toxicity, and patient factors. MARIPOSA-2 vs PALOMA-3 choices are influenced by efficacy in resistant mutations and safety profiles, per European Society for Medical Oncology 2023/2024 and American Society of Clinical Oncology 2024 data.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Looking at treatment sequencing, how do you approach second-line therapy after:
- MARIPOSA regimen?
- What factors influence your choice between MARIPOSA-2 and PALOMA-3?
- MARIPOSA-2: Passaro A, et al. ESMO Congress 2023. Abs LBA15, Popat S, et al. ESMO 2024. Abs LBA54.
- PALOMA-3: Leighl NB, et al. ASCO 2024. Abs LBA8505.
Advertisement
Related to this article
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.
The HER2-directed ADC produced confirmed responses across both biomarker-defined cohorts of advanced salivary gland carcinoma.
The FDA approved iberdomide plus daratumumab and dexamethasone for relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
Trastuzumab Rezetecan Elicits High ORR in HER2-High and HER2-Low Salivary Gland Carcinoma
5